Longevity Science
Conference

Daniel Ives is the CEO and founder of Shift Bioscience, a company dedicated to reversing cellular aging using AI-guided cellular rejuvenation techniques. With a background in mitochondrial biology from the University of Cambridge, Daniel has been at the forefront of developing innovative solutions to combat age-related diseases. His work focuses on leveraging advanced machine learning and epigenetic aging clocks to discover new therapeutic interventions that can extend human healthspan.

Caitlin Lewis is the Director of Project Pipeline and Strategy at the LEV Foundation, where she plays a crucial role in evaluating progress and identifying therapeutic targets in the field of longevity. Introduced to the longevity field in 2017 through the SENS Research Foundation's MitoSENS project, Caitlin has been instrumental in developing strategies for nascent projects and facilitating their advancement. Her work focuses on promoting research to prevent and reverse age-related diseases, aiming to improve human healthspan.

Peter Fedichev is an entrepreneur and scientist with over 20 years of experience in academic research and biotech business. He is the founder of Gero, a longevity startup focused on developing therapies to extend a healthy human lifespan. Peter's scientific background lies in condensed matter physics, biophysics, and bioinformatics. His work aims to uncover the principles of aging and develop interventions to promote healthy longevity.

Matthew "Oki" O'Connor is the Co-CEO of Cyclarity Therapeutics, a company focused on developing treatments for cardiovascular diseases through innovative cyclodextrin technology. With a Ph.D. in Biochemistry and extensive research experience in aging and regenerative medicine, O'Connor has made significant contributions to the field. His work aims to eliminate toxic oxidized cholesterol, a major factor in atherosclerosis, and improve overall healthspan.

Marco Quarta is a distinguished scientist and entrepreneur, currently serving as the Co-founder, President & CSO of Rubedo Life Sciences. He holds a Ph.D. in Neuroscience from the University of Padua and has conducted post-doctoral research in aging and stem cell biology at Stanford University. Marco has over 20 years of experience in the fields of aging, stem cells, and regenerative medicine, and has co-founded several biotech companies. His work focuses on developing treatments for age-related diseases and extending healthspan by targeting pathological cells involved in the aging process.

Mahdi Moqri, Ph.D., is a Harvard Faculty member, computational biologist, and the founding director of the Biomarkers of Aging Consortium. His interdisciplinary expertise spans omics, bioinformatics, and computational methods to explore the molecular mechanisms of aging and develop innovative therapies for age-related diseases. As director, he leads international collaborations to validate blood-based biomarkers of aging, with research published in Cell and Nature Medicine. Previously, Dr. Moqri completed a postdoctoral fellowship at Stanford University and has raised over $1M to advance aging research. He is passionate about enhancing human health and longevity.

Reason is the co-founder and CEO of Repair Biotechnologies, pioneering solutions to combat aging and extend human healthspan. An active angel investor in the longevity sector, he has backed companies like Oisin Biotechnologies and Leucadia Therapeutics. As a passionate patient advocate, Reason supports fundraising and outreach efforts for organizations like the Methuselah Foundation and SENS Research Foundation. He is also the founder and writer of Fight Aging!, a prominent biotechnology news and commentary platform. Before his biotechnology career, Reason was a consultant in the software industry.

Vera Gorbunova is a distinguished biologist and the Doris Johns Cherry Professor at the University of Rochester, where she also co-directs the Rochester Aging Research Center. She earned her B.Sc. from Saint Petersburg State University and her Ph.D. from the Weizmann Institute of Science. Gorbunova's pioneering research focuses on the mechanisms of aging and cancer resistance, particularly in long-lived mammals like the naked mole rat. Her work has identified high molecular weight hyaluronan as a key mediator of cancer resistance, earning her recognition and numerous awards in the field of aging research.

Martin Borch Jensen is the co-founder and CSO of Gordian Biotechnology, focused on developing pooled in vivo therapeutic screenings to address aging-related diseases. He has a rich background in aging biology, mitochondrial health, and neurodegenerative diseases, with key publications in Cell Metab and Nature. Jensen holds a prestigious NIH K99/R00 award and previously studied DNA repair mechanisms in aging at the National Institute on Aging. In addition to his leadership role at Gordian, he serves on multiple scientific advisory boards and co-authored a popular science book on intermittent fasting and aging.

Mike Conboy, PhD, is a leading Research Scientist at the University of California, Berkeley, specializing in aging and rejuvenation research. As a key member of the Conboy Laboratory, he collaborates with his wife, Irina, to explore how aging affects stem cells and tissues. His work on heterochronic parabiosis and blood apheresis has shed light on potential therapies to reverse age-related damage and enhance tissue repair. Dr. Conboy is dedicated to advancing methods that could significantly improve healthspan and extend the healthy human lifespan.

Yuri Deigin is an entrepreneur, scientist, and biotech innovator with a deep focus on life sciences and longevity research. He is the co-founder and CEO of YouthBio Therapeutics, a company dedicated to developing cutting-edge gene therapies aimed at reversing aging processes at the cellular level. With a background in biotechnology, drug development, and artificial intelligence, Yuri has been at the forefront of translating scientific discoveries into practical solutions to combat age-related decline. His work is driven by a passion for advancing rejuvenation technologies to extend healthy human lifespan and improve quality of life.

Eleanor Sheekey is a dynamic scientist and communicator, blending cutting-edge research with engaging education. As a Postdoctoral Researcher at RIKEN, she explores skin aging and extracellular matrices, building on her PhD at the Cancer Research UK Cambridge Institute, where she studied p53 and cellular senescence. Creator of the Sheekey Science Show YouTube channel, Eleanor simplifies complex science for almost 50K subscribers, covering topics like longevity and CRISPR. She’s also a guest lecturer and director of Sheekey Science Solutions. Passionate about knowledge-sharing, Eleanor’s work inspires curiosity and advances understanding in biomedicine.

Dr. Keshav K. Singh, a globally recognized expert in longevity and mitochondrial science, is the founder and Chief Scientific Officer of Yuva Biosciences, a trailblazing biotech company focused on extending healthspan through mitochondrial innovation. As the Joy and Bill Harbert Endowed Chair at UAB and founding editor of Mitochondrion, Dr. Singh has authored over 100 publications and three books, earning honors like Stanford’s Top 2% Scientists and Newsweek’s Innovation Hero. A dynamic thought leader, he pioneers transformative research at the intersection of aging, health disparities, and mitochondrial genetics.

Kevin Perrott is an entrepreneur and scientist with over 15 years of experience at the intersection of biotechnology and longevity research. He is the founder and CEO of OpenCures, an organization dedicated to empowering individuals to harness the potential of self-directed health data and cutting-edge scientific insights to improve their longevity. Kevin’s background spans molecular biology, biogerontology, and bioinformatics. His work focuses on advancing personalized approaches to health optimization and developing therapies to combat the root causes of aging.

Alan Tomusiak is a researcher specializing in the biology of aging, with a focus on epigenetics and immunology. For his PhD, he studied in the Verdin Lab at the Buck Institute for Research on Aging. His research focuses on developing novel epigenetic clocks that are resistant to changes in immune cell composition, aiming to improve the accuracy of biological age predictions. Alan has also explored the effects of senolytic compounds on DNA methylation clocks, contributing to the understanding of how these interventions may influence biological aging. Through his work, Alan aims to uncover the molecular mechanisms underlying aging and develop interventions to promote healthy longevity.

Nathan Price is a scientist and entrepreneur with extensive experience in systems biology and biomedical research. He is the Chief Scientific Officer at Thorne and the Co-Director and Professor at the Buck Institute for Research on Aging. Nathan’s work focuses on leveraging multi-omics data, AI, and personalized health strategies to optimize human longevity and disease prevention. His research spans computational biology, precision medicine, and the development of interventions to promote healthy aging. Through his leadership in both academia and industry, he aims to transform healthcare by advancing science-driven approaches to longevity and well-being.